A June 2025 press story noted NICE considers a multi-year appraisal to decide on GLP-1s, mindful of both clinical data and cost (reflecting NICEs rigor) ( [46] )
Serious side effects from GLP-1s are rare, but knowing what to watch for ensures your medical weight loss journey stays safe and effective
Another trial published in The Lancet in 2017 demonstrated that exenatide (Byetta) improved motor function in patients with Parkinson's disease, with some exploratory cognitive measures showing potential benefit, though the study was limited by small sample size and short duration
Between the medication itself, supplements, potential dermatology visits, PRP treatments, and peptide products, costs can add up
The earliest it could hit the market would be late 2026, though it's more likely to drop in 2027